Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
M1 Kliniken focuses on beauty after pharma sale and shows rising profitability
M1 Kliniken is concentrating fully on the profitable beauty segment after selling its pharma business, which grew by 11% in H1 to €56.9m. Segment EBIT rose 23.8% to €18.6m and the margin climbed to 32.7%; management targets 2029 revenue of €200–300m and an EBIT margin of at least 20%. With a major shareholder (MPH Health Care) holding over 66% and low free float, M1 Kliniken is seen as an attractive takeover or going-private candidate; a price target of €26.50 (about 31% upside) is cited. » Más en finanzen.net
M1 Kliniken posts double-digit revenue and margin growth in beauty business
Adjusted figures show M1 Kliniken’s core business increased revenue in H1 2026 by 11% to €56.9m and improved EBIT by almost 24% to €18.6m; in Q2 revenue growth accelerated to around 16%. The prior sharp decline in group metrics resulted from the deconsolidation and sale of wholesale subsidiary Haemato Pharm. Management confirms a mid-term target of €200–300m revenue by 2029 with an EBIT margin of at least 20% (H1 margin: >32%). Analysts raised the price target, leaving upside of almost 50%; the P/E for 2026 is expected to be below 14. » Más en finanzen.net
M1 Kliniken impresses with robust growth and a strong dividend increase
M1 Kliniken's stock has risen in recent months to close to its all-time high. The Düsseldorf-based company reports robust growth and surprised with a significantly increased dividend. If the ambitious forecasts are met, the authors see further upside potential for the share price. » Más en finanzen.net
M1 Kliniken boosts revenue, sharply raises dividend and confirms ambitious guidance
M1 Kliniken reports for 2025 a revenue increase of 7.4% to €364.3m and EBIT growth of 29.2% to €34.6m; the beauty clinics recorded revenue growth of 11.2% and an EBIT gain of 41.5%. The dividend is to rise from €0.50 to €1.20 per share, equivalent to a yield of more than 6%. Management reaffirms the mid‑term guidance of €200–300m in revenue and a sustainable EBIT margin of 20% by 2029; acquisitions are not excluded as a growth driver. A reduced share count due to buybacks and a cash reserve of more than €30m support further upside potential for the stock. » Más en finanzen.net
M1 Kliniken approves 2025 financial statements and proposes dividend of EUR 1.20 per share
The supervisory board of M1 Kliniken has approved the annual and consolidated financial statements for 2025 submitted by the management board. The supervisory board and management board propose a dividend of EUR 1.20 per dividend-entitled share to the general meeting. The 2025 annual report is expected to be published on 20 May 2026. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 76,6 M | - |
| Beneficio bruto | 23,6 M | - |
| Beneficio neto | 9,72 M | - |
| EBITDA | 17,68 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 361,08 M € |
Número de acciones | 18,56 M |
Máximo/mínimo de 52 semanas | 21,70 € - 13,62 € |
Rentabilidad por dividendo | 6,09 % |
Dividendos TTM | 1,20 € |
Beta | 0,99 |
Ratio P/E | 17,85 |
Ratio PEG | 1,32 |
Ratio P/B | 2,93 |
Ratio P/S | 1,40 |
Perfil de la empresa
M1 Kliniken AG, junto con sus filiales, opera centros médicos de cirugía estética y plástica en Alemania, Austria, Países Bajos, Suiza, Reino Unido, Croacia y Australia. La empresa opera en dos segmentos, Beauty y Trade. Desarrolla y comercializa productos farmacéuticos, médicos y de tecnología médica para la medicina estética y la dermatología cosmética, así como comercia con productos y dispositivos farmacéuticos, biosimilares y otros productos médicos en las áreas de oncología, VIH, reumatismo, neurología, enfermedades cardiovasculares y estupefacientes. La empresa también se dedica a la adquisición, gestión y venta de bienes inmuebles, principalmente en el sector sanitario. Ofrece sus productos a médicos, farmacias y mayoristas bajo la marca M1 Select. La empresa opera una red de centros ambulatorios de especialistas y un centro quirúrgico especializado, además de 46 centros de especialistas bajo la marca M1 Med Beauty. M1 Kliniken AG se fundó en 2007 y tiene su sede en Berlín, Alemania. M1 Kliniken AG opera como filial de MPH Health Care AG.
| Nombre | M1 Kliniken |
| CEO | Attila Strauss |
| Sede | Berlin,
be Alemania |
| Sitio web | |
| Sector | Salud |
| Industria | Proveedores y servicios sanitarios |
| Salida a bolsa | 14/09/2015 |
| Empleados | 280 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
XETRA | M12.DE |
Pnk | MKLNF |
Frankfurt | M12.F |
Düsseldorf | M12.DU |
Hamburg | M12.HM |
München | M12.MU |